The ACG has released new clinical guidelines for the management of ulcerative colitis and Crohn’s disease in adult ...

Investors are swarming AbbVie with bullish bets, as call options surged past expectations and sent volatility ticking up.

North Chicago, Illinois-based AbbVie Inc. (ABBV) discovers, develops, manufactures, and sells pharmaceuticals worldwide. With ...

AbbVie’s stock has tumbled nearly 13% over three months, rattled by global tariffs and the looming shadow of Humira’s patent ...

ABBV drops 12.6% in three months, but rising Skyrizi and Rinvoq sales, pipeline strength, and 2025 growth outlook support staying invested.

AbbVie posted strong Q1 2025 results and raised guidance, but early-stage obesity pipeline and fair valuation limit upside.

Absci has entered the clinic with its AI-designed antibody, dosing first volunteers in a trial targeting TL1A for ...

Apple tops our list of the stocks that the best fund managers are selling, yet it remains a widely held stock among these ...

Kaddis said insurers are locked in a cat-and-mouse game with drugmakers as the insurance sector invests in biosimilars and ...

Recently, AbbVie reported solid Q1 2025 results, with its immunology drugs Skyrizi and Rinvoq delivering robust sales and offsetting the decline in Humira revenue due to competition from biosimilars.

AbbVie Q4 adjusted EPS of $2.16 beat estimates, with strong sales of Skyrizi (+57.9%) and Rinvoq (+47.1%) boosting revenue growth. AbbVie raises 2027 revenue forecast for Skyrizi and Rinvoq to $31 ...

AbbVie is increasing its 2027 revenue forecast for Skyrizi and Rinvoq to over $31 billion, up $4 billion from the previous guidance. This includes over $20 billion for Skyrizi and over $11 billion ...